cd28 pe cy7  (Miltenyi Biotec)

Journal: Cancers

Article Title: Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination

doi: 10.3390/cancers14184464

Figure Lengend Snippet: CD8 T-cell responses to S, M and N peptides of SARS-CoV-2 proteins. Paired backgrounds from technical controls were removed from the data. ( A – C ) Percentage of S-specific CD8 T-cells in PBMCs stimulated with S-peptides in healthy donors and oncologic patients. ( D – F ) Percentage of S-specific CD8 T-cells in PBMCs stimulated with M-peptides in healthy donors and oncologic patients. ( G – I ) Percentage of S-specific CD8 T-cells in PBMCs stimulated with N-peptides in healthy donors and oncologic patients. ( A , B , D , E , G , H ) Significance was tested with Kruskal–Wallis tests, followed by Dunn’s test. ( J ) Percentage of activated CD8 T-cells after stimulation with S- or M-specific peptides in O-CoV donors. ( C , F , I , J ) U of Mann-Whitney was used to test for significance. ( K ) Relative percentages of CD8 T-cell differentiation phenotypes in the indicated groups of healthy donors and oncologic patients. Means and error bars (standard deviations) are shown. N, CM, EM and E, indicate naïve-stem cell (CD62L+ CD45RA+), central memory (CD62L+ CD45RA neg ), effector memory (CD62L neg CD45RA neg ) and effector (CD62L neg CD45RA+) phenotypes. Relevant statistical comparisons are detailed in . ( L ) Relative percentages of CD8 T-cell differentiation phenotypes in the indicated groups of healthy donors and oncologic patients according to CD27 neg CD28 expression profiles. CD27 + CD28 + , CD27 neg CD28+ and CD27 + CD28 + indicate poorly differentiated, intermediate differentiated and highly differentiated T-cell phenotypes. H-N/N—non-vaccinated, non-COVID-19 donors; H-CoV—healthy donors with previous COVID-19 infection; H-V—vaccinated healthy donor; H-CoV-V—vaccinated healthy donor with previous COVID-19; O-CoV—oncologic patient with previous COVID-19; O-V—vaccinated oncologic patients; O-CoV-V—vaccinated oncologic patients with previous COVID-19; *, ** and **** indicate significant ( p < 0.05), very significant ( p < 0.01) and very highly significant ( p < 0.0001) differences, respectively.

Article Snippet: The following fluorochrome-conjugated antibodies were used: CD14-Violet Fluor 450 (Ref 75-0149-T100, TONBO, San Diego, CA, USA), CD11b-PerCP-Cy5-5 (Ref 65-0112-U1, TONBO), CD62L-APC (Ref 130-113-617, Miltenyi, North Rhine-Westphalia, Germany), CD66b-APC-Cy7 (Ref 130-120-146, Miltenyi), CD54-FITC (Ref 130-104-214, Miltenyi), CD19-PE (Ref 130-113-731, Miltenyi), CD3-APC (Ref 130-113-135, Miltenyi), CD8-APC-Cy7 (Ref 130-110-681, Miltenyi), CD4-FITC (Ref 130-114-531, Miltenyi), CD27-PE (Ref 50-0279-T100, TONBO), CD28-PE-Cy7 (Ref 130-126-316, Miltenyi).

Techniques: MANN-WHITNEY, Cell Differentiation, Expressing, Infection

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: The use of peripheral CD3 + γδ + Vδ2 + T lymphocyte cells in combination with the ALBI score to predict immunotherapy response in patients with advanced hepatocellular carcinoma: a retrospective study

doi: 10.1007/s00432-024-05896-y

Figure Lengend Snippet: Peripheral lymphocyte subsets in patients with advanced HCC.

Article Snippet: For intracellular cytokine expression, cells were stimulated with phorbol myristate acetate (PMA, Sigma-Aldrich, Germany) and brefeldin A (BFA, BD Biosciences, USA) at 37 ºC for 5 h. The following monoclonal antibodies were used: APC-H7 Mouse Anti-Human CD3 (BD Bioscience, USA); BV605 Mouse Anti-Human CD4 (BD Bioscience, USA); FITC Mouse Anti-Mouse CD8 (BD Bioscience, USA); BV421 Mouse Anti-Human γδ TCR (BD Bioscience, USA); PE Mouse Anti-Human CD279 (BD Bioscience, USA); APC Anti-Human CD366 (Tim-3, BioLegend, USA); Brilliant Violet 510 Anti-Human TCR Vδ2 (BioLegend, USA); PerCP-Vio 700 Anti-Human TCR Vδ1 (Miltenyi Biotec, Germany); and PE-Cy7 Mouse Anti-Human CD28 (BD Bioscience, USA).

Techniques:

Journal: Immunity

Article Title: CD8 + T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor

doi: 10.1016/j.immuni.2022.12.002

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: anti-human CD28 (Pe-Cy7) , Thermofisher , clone: CD28.2, RRID: AB_1944363.

Techniques: Blocking Assay, Recombinant, Staining, Selection, Enzyme-linked Immunosorbent Assay, Software